Last quarter (Q4 2022), Allergy Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Allergy Therapeutics's net income was $―. See Allergy Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 23	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	$ ―	$ 59.59M	$ 72.77M	$ 84.33M	$ 78.20M	$ 73.72M
Cost of Revenue	$ ―	$ 26.34M	$ 23.26M	$ 22.11M	$ 20.20M	$ 18.38M
Gross Profit	$ ―	$ 33.24M	$ 49.51M	$ 62.23M	$ 58.00M	$ 55.34M
Operating Expense	$ ―	$ 73.75M	$ 62.49M	$ 58.19M	$ 49.69M	$ 50.95M
Operating Income	$ ―	$ -40.51M	$ -12.98M	$ 4.03M	$ 8.31M	$ 4.39M
Net Non Operating Interest Income Expense	$ ―	$ -2.11M	$ -412.00K	$ 374.00K	$ 238.00K	$ 98.00K
Other Income Expense	$ ―	$ -856.00K	$ -740.00K	$ ―	$ ―	$ ―
Pretax Income	$ ―	$ -41.77M	$ -12.66M	$ 3.66M	$ 8.07M	$ 4.29M
Tax Provision	$ ―	$ 1.30M	$ 1.12M	$ 771.00K	$ 1.01M	$ 826.00K
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -43.07M	$ -13.78M	$ 2.89M	$ 7.06M	$ 3.47M
Basic EPS	$ ―	$ -0.06	$ -0.02	$ ―	$ 0.01	$ 0.01
Diluted EPS	$ ―	$ -0.06	$ -0.02	$ ―	$ 0.01	$ 0.01
Basic Average Shares	$ ―	$ 670.36M	$ 642.99M	$ 639.19M	$ 636.17M	$ 632.84M
Diluted Average Shares	$ ―	$ 670.36M	$ 642.99M	$ 676.66M	$ 673.49M	$ 669.70M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ 100.10M	$ 85.75M	$ -80.30M	$ -69.89M	$ -69.33M
Net Income From Continuing And Discontinued Operation	$ ―	$ -43.07M	$ -13.78M	$ 2.89M	$ 7.06M	$ 3.47M
Normalized Income	$ ―	$ -33.83M	$ -10.25M	$ 2.96M	$ 6.54M	$ 3.48M
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ ―	$ -39.33M	$ -11.99M	$ 4.15M	$ 8.57M	$ 4.49M
EBITDA	$ ―	$ -35.10M	$ -7.82M	$ 4.15M	$ 8.57M	$ 4.49M

Currency in USD

Allergy Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing